Literature DB >> 29063349

Electroconvulsive therapy does not alter the synaptic protein neurogranin in the cerebrospinal fluid of patients with major depression.

Laura Kranaster1, Kaj Blennow2,3, Henrik Zetterberg2,3,4,5, Alexander Sartorius6.   

Abstract

Neurogranin (Ng) is a dendritic protein associated with synaptic plasticity, proposed to be a novel biomarker to measure synaptic dysfunction and degeneration in Alzheimer's disease. Since electroconvulsive therapy (ECT) has been suggested to facilitate neurogenesis and neural plasticity, we tested whether ECT could modify CSF Ng concentrations measured before and after a course of ECT in 12 patients with major depression. CSF Ng concentrations did not change, but baseline levels were positively correlated with the therapeutic response.

Entities:  

Keywords:  Affective disorder; Cerebrospinal fluid; Depression; ECT; Electroconvulsive therapy; Neurogranin

Mesh:

Substances:

Year:  2017        PMID: 29063349     DOI: 10.1007/s00702-017-1802-z

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  21 in total

1.  Neurogranin: immunocytochemical localization of a brain-specific protein kinase C substrate.

Authors:  A Represa; J C Deloulme; M Sensenbrenner; Y Ben-Ari; J Baudier
Journal:  J Neurosci       Date:  1990-12       Impact factor: 6.167

2.  Handling results below the level of detection.

Authors:  T L Ogden
Journal:  Ann Occup Hyg       Date:  2010-01-12

3.  Structural Plasticity of the Hippocampus and Amygdala Induced by Electroconvulsive Therapy in Major Depression.

Authors:  Shantanu H Joshi; Randall T Espinoza; Tara Pirnia; Jie Shi; Yalin Wang; Brandon Ayers; Amber Leaver; Roger P Woods; Katherine L Narr
Journal:  Biol Psychiatry       Date:  2015-03-05       Impact factor: 13.382

4.  Electroconvulsive therapy enhances endocannabinoids in the cerebrospinal fluid of patients with major depression: a preliminary prospective study.

Authors:  Laura Kranaster; Carolin Hoyer; Suna Su Aksay; Jan Malte Bumb; F Markus Leweke; Christoph Janke; Manfred Thiel; Beat Lutz; Laura Bindila; Alexander Sartorius
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2017-03-24       Impact factor: 5.270

5.  Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease.

Authors:  Hlin Kvartsberg; Flora H Duits; Martin Ingelsson; Niels Andreasen; Annika Öhrfelt; Kerstin Andersson; Gunnar Brinkmalm; Lars Lannfelt; Lennart Minthon; Oskar Hansson; Ulf Andreasson; Charlotte E Teunissen; Philip Scheltens; Wiesje M Van der Flier; Henrik Zetterberg; Erik Portelius; Kaj Blennow
Journal:  Alzheimers Dement       Date:  2014-12-19       Impact factor: 21.566

Review 6.  RC3/neurogranin, a postsynaptic calpacitin for setting the response threshold to calcium influxes.

Authors:  D D Gerendasy; J G Sutcliffe
Journal:  Mol Neurobiol       Date:  1997-10       Impact factor: 5.590

7.  Antibodies to postsynaptic PKC substrate neurogranin prevent long-term potentiation in hippocampal CA1 neurons.

Authors:  N B Fedorov; P Pasinelli; A B Oestreicher; P N DeGraan; K G Reymann
Journal:  Eur J Neurosci       Date:  1995-04-01       Impact factor: 3.386

8.  Polymorphisms in NRGN are associated with schizophrenia, major depressive disorder and bipolar disorder in the Han Chinese population.

Authors:  Zujia Wen; Jianhua Chen; Raja Amjad Waheed Khan; Meng Wang; Zhijian Song; Zhiqiang Li; Jiawei Shen; Wenjin Li; Yongyong Shi
Journal:  J Affect Disord       Date:  2016-01-13       Impact factor: 4.839

9.  Cerebrospinal fluid tau, neurogranin, and neurofilament light in Alzheimer's disease.

Authors:  Niklas Mattsson; Philip S Insel; Sebastian Palmqvist; Erik Portelius; Henrik Zetterberg; Michael Weiner; Kaj Blennow; Oskar Hansson
Journal:  EMBO Mol Med       Date:  2016-10-04       Impact factor: 12.137

10.  Electroconvulsive therapy induces neurogenesis in frontal rat brain areas.

Authors:  Dragos Inta; Juan M Lima-Ojeda; Thorsten Lau; Wannan Tang; Christof Dormann; Rolf Sprengel; Patrick Schloss; Alexander Sartorius; Andreas Meyer-Lindenberg; Peter Gass
Journal:  PLoS One       Date:  2013-07-26       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.